StarZero All shows Try the podcast clipper →

drug development

3 statements across 2 episodes · 1 bullish · 1 bearish · 2 people on the record · first statement Jan 14, 2019 by Jean Hynes · across every show →

Everything said about drug development, oldest first

Jan 14, 2019 neutral
Insight
Hynes: Overly narrowing healthcare analysts' focus blinds them to 10-year industry changes
“The reason why 12 is enough is it's a very long cycle industry. So it is an industry that is, even though there's a lot of change happening, that change happens over 10 years to bring a drug to the market. And so we want to make sure we're covering all the com…”
Jean Hynes Jan 14, 2019 ▶ 16:06 Jean Hynes – Inside Wellington Management (Capital Allocators, EP.82)
Apr 24, 2023 bearish
Opinion
Rod Wong: Payer pushback on drug pricing is biotech's top long-term risk
“You know, I think one of the things I'm most concerned about is payers and the pressure that we're seeing on paying for innovation in drug development. That's probably my number one long-term concern.”
Rod Wong Apr 24, 2023 ▶ 52:59 Rod Wong – Empty Rooms: Innovation in Biotech at RTW (Capital Allocators, EP. 310)
Apr 24, 2023 positive
Opinion
Wong: Drug development enjoys relatively strong value capture via pricing
“Drug development is one of the sectors that has relatively good value capture via pricing.”
Rod Wong Apr 24, 2023 ▶ 14:46 Rod Wong – Empty Rooms: Innovation in Biotech at RTW (Capital Allocators, EP. 310)
Made with StarZero

Turn any episode into a week of clips.

This entire site, over 700 episodes transcribed, diarized, checked and made playable, runs on the StarZero media pipeline. Drop in your own episode and the podcast clipper finds the moments worth sharing, cuts them, captions them, and reframes them for every feed.

Try the podcast clipper Learn more